MRNA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -117.16% compared to Moderna's net margin of 10.87%. Moderna's return on equity of -29.09% beat Biogen's return on equity of 10.33%.

Moderna has a consensus price target of $49.96, signalling upside risk potential of 83.55%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Biogen quarterly revenues of $2.5B. Moderna's net income of -$1.1B is lower than Biogen's net income of $266.7M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.30x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -117.16% compared to Moderna's net margin of 16.72%. Moderna's return on equity of -29.09% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Moderna has a consensus price target of $49.96, signalling upside risk potential of 83.55%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.87 which suggests that it could grow by 53.04%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are larger than Biomarin Pharmaceutical quarterly revenues of $747.3M. Moderna's net income of -$1.1B is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Moderna's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 28.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.30x versus 4.40x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -117.16% compared to Moderna's net margin of 24.16%. Moderna's return on equity of -29.09% beat Sarepta Therapeutics's return on equity of 20.83%.

Moderna has a consensus price target of $49.96, signalling upside risk potential of 83.55%. On the other hand Sarepta Therapeutics has an analysts' consensus of $147.33 which suggests that it could grow by 143.77%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are larger than Sarepta Therapeutics quarterly revenues of $658.4M. Moderna's net income of -$1.1B is lower than Sarepta Therapeutics's net income of $159M. Notably, Moderna's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 26.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.30x versus 3.54x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -117.16% compared to Moderna's net margin of 31.35%. Moderna's return on equity of -29.09% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Moderna has a consensus price target of $49.96, signalling upside risk potential of 83.55%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 1.31%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Moderna's net income of -$1.1B is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Moderna's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.30x versus 11.62x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.